Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Minimizing Foaming During Mixing – V 2.0

Posted on By

Elixir Department: SOP for Minimizing Foaming During Mixing – V 2.0

Standard Operating Procedure for Minimizing Foaming During Mixing in Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/079/2025
Supersedes SOP/ELX/079/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To outline the procedure for minimizing foam formation during the mixing process of elixir formulations, thereby ensuring uniformity, clarity, and quality of the product.

2. Scope

This SOP applies to all elixir batches manufactured in the Elixir Department where foaming during mixing is likely due to the nature of active ingredients, surfactants, excipients, or mixing speed.

3. Responsibilities

  • Production Operator:
    • Follow instructions to control speed, sequence, and defoamer addition.
    • Monitor foam generation during the mixing process.
  • Production Supervisor:
    • Ensure defoaming strategies are implemented as per the batch record.
    • Report excessive foam incidents to QA for impact assessment.
  • QA Officer:
    • Review foam control procedures and approve use of defoaming agents where applicable.
See also  Elixir Department: SOP for Microbial Limit Testing - V 2.0

4. Accountability

The Production Head is accountable for ensuring the implementation of foam control measures during mixing and maintaining batch quality.

5. Procedure

5.1 Preventive Measures

  1. Use low-shear mixers where applicable for foam-prone formulations.
  2. Control mixing speed:
    • Start at low RPM (100–200) and increase gradually.
    • Avoid sudden changes in speed or direction.
  3. Use properly sized mixing tanks to avoid splashing and turbulence.

5.2 Sequence of Ingredient Addition

  1. Follow the established sequence of ingredient addition in the BMR.
  2. Add surfactants or foaming agents last and under controlled mixing conditions.
  3. Avoid pouring powders rapidly into the vortex.
See also  Elixir Department: SOP for Recording Parameters in BMR - V 2.0

5.3 Use of Defoaming Agents (if applicable)

  1. Use only QA-approved defoaming agents (e.g., simethicone emulsion).
  2. Add the agent slowly under stirring after primary mixing is complete.
  3. Document usage in the BMR, including quantity and batch number of the defoamer.

5.4 Monitoring Foam Formation

  1. Visually inspect the tank during and after mixing for foam layer formation.
  2. If foam exceeds 10% of surface volume:
    • Stop agitation temporarily.
    • Skim excess foam using a sanitized ladle, if needed.

5.5 Documentation

  1. Record observations related to foam formation and any corrective actions in the Mixing Observation Log (Annexure-1).
  2. Attach supporting details to the BMR.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • BMR: Batch Manufacturing Record
  • QA: Quality Assurance
  • RPM: Revolutions Per Minute
See also  Elixir Department: SOP for Prevention of Aeration During Mixing - V 2.0

7. Documents

  1. Mixing Observation Log (Annexure-1)
  2. Batch Manufacturing Record (BMR)
  3. Defoamer Approval Sheet (if used)

8. References

  • WHO TRS 1010 – GMP for Pharmaceutical Products
  • ICH Q8 – Pharmaceutical Development

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Mixing Observation Log

Date Batch No. RPM Used Foam Level Observed Action Taken Operator
11/04/2025 ELX-1018 300 Moderate foam Reduced speed, added 1 ml simethicone Rajesh Kumar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP QA Head
11/04/2025 2.0 Added preventive foam control practices Process Consistency QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Cross-Verification of Dispensed Materials – V 2.0
Next Post: API Manufacturing: SOP for Sample Tracking and Lab Numbering System – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version